These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 37166346)

  • 1. The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
    Akazawa Y; Igawa S; Yamada K; Yamamoto H; Yagami Y; Kaizuka N; Manaka H; Kasajima M; Nakahara Y; Sato T; Mitsufuji H; Yokoba M; Kubota M; Sasaki J; Naoki K
    Oncology; 2023; 101(11):685-694. PubMed ID: 37166346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
    Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
    Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.
    Kasahara N; Imai H; Naruse I; Tsukagoshi Y; Kotake M; Sunaga N; Kaira K; Maeno T; Asao T; Hisada T
    Thorac Cancer; 2020 Aug; 11(8):2188-2195. PubMed ID: 32495520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
    Ono T; Igawa S; Kurahayashi S; Okuma Y; Sugimoto A; Kusuhara S; Ozawa T; Fukui T; Sasaki J; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Naoki K
    Invest New Drugs; 2020 Jun; 38(3):885-893. PubMed ID: 32157598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
    Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
    Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
    Hung LJ; Hsu PC; Yang CT; Kuo CS; Chang JW; Huang CY; Chang CF; Wu CE
    Aging (Albany NY); 2024 Jan; 16(1):550-567. PubMed ID: 38194721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
    Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
    Arrieta O; Catalán R; Guzmán-Vazquez S; Barrón F; Lara-Mejía L; Soto-Molina H; Ramos-Ramírez M; Flores-Estrada D; de la Garza J
    BMC Cancer; 2020 Sep; 20(1):829. PubMed ID: 32873256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
    BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
    Sari M; Aydiner A
    J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.